Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 6
1988 2
1989 4
1990 6
1991 1
1992 1
1993 2
1994 2
1995 3
1997 3
1998 3
1999 2
2000 2
2001 3
2002 2
2003 1
2004 1
2005 2
2007 2
2009 1
2010 2
2011 2
2012 1
2013 4
2014 4
2015 6
2016 6
2017 4
2018 8
2019 6
2020 6
2021 14
2022 9
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
Siciliano MA, Caridà G, Ciliberto D, d'Apolito M, Pelaia C, Caracciolo D, Riillo C, Correale P, Galvano A, Russo A, Barbieri V, Tassone P, Tagliaferri P. Siciliano MA, et al. Among authors: caracciolo d. ESMO Open. 2022 Jun;7(3):100465. doi: 10.1016/j.esmoop.2022.100465. Epub 2022 Apr 12. ESMO Open. 2022. PMID: 35427835 Free PMC article.
Mir-221/222 are promising targets for innovative anticancer therapy.
Di Martino MT, Rossi M, Caracciolo D, Gullà A, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: caracciolo d. Expert Opin Ther Targets. 2016 Sep;20(9):1099-108. doi: 10.1517/14728222.2016.1164693. Epub 2016 Mar 21. Expert Opin Ther Targets. 2016. PMID: 26959615 Review.
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Tassone P, Di Martino MT, Arbitrio M, Fiorillo L, Staropoli N, Ciliberto D, Cordua A, Scionti F, Bertucci B, Salvino A, Lopreiato M, Thunarf F, Cuomo O, Zito MC, De Fina MR, Brescia A, Gualtieri S, Riillo C, Manti F, Caracciolo D, Barbieri V, Di Paola ED, Di Francesco AE, Tagliaferri P. Tassone P, et al. Among authors: caracciolo d. J Hematol Oncol. 2023 Jun 26;16(1):68. doi: 10.1186/s13045-023-01468-8. J Hematol Oncol. 2023. PMID: 37365583 Free PMC article. Clinical Trial.
The potential role of miRNAs in multiple myeloma therapy.
Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P. Caracciolo D, et al. Expert Rev Hematol. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041. Epub 2018 Sep 12. Expert Rev Hematol. 2018. PMID: 30148649 Review.
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
Riillo C, Polerà N, Di Martino MT, Juli G, Hokanson CA, Odineca T, Signorelli S, Grillone K, Ascrizzi S, Mancuso A, Staropoli N, Caparello B, Cerra M, Nisticò G, Tagliaferri P, Crea R, Caracciolo D, Tassone P. Riillo C, et al. Among authors: caracciolo d. J Transl Med. 2023 May 4;21(1):301. doi: 10.1186/s12967-023-04101-x. J Transl Med. 2023. PMID: 37143061 Free PMC article.
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Caracciolo D, Polerà N, Belmonte B, Conforti F, Signorelli S, Gulino A, Staropoli N, Tuccillo FM, Bonelli P, Juli G, Grillone K, Ascrizzi S, Cirillo M, Migale L, Ballerini A, Pelizon C, Di Martino MT, Tagliaferri P, Riillo C, Tassone P. Caracciolo D, et al. Br J Haematol. 2024 Feb;204(2):555-560. doi: 10.1111/bjh.19183. Epub 2023 Nov 14. Br J Haematol. 2024. PMID: 37963444
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma.
Scionti F, Juli G, Rocca R, Polerà N, Nadai M, Grillone K, Caracciolo D, Riillo C, Altomare E, Ascrizzi S, Caparello B, Cerra M, Arbitrio M, Richter SN, Artese A, Alcaro S, Tagliaferri P, Tassone P, Di Martino MT. Scionti F, et al. Among authors: caracciolo d. J Exp Clin Cancer Res. 2023 Mar 27;42(1):71. doi: 10.1186/s13046-023-02633-0. J Exp Clin Cancer Res. 2023. PMID: 36967378 Free PMC article.
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.
Di Martino MT, Arbitrio M, Caracciolo D, Cordua A, Cuomo O, Grillone K, Riillo C, Caridà G, Scionti F, Labanca C, Romeo C, Siciliano MA, D'Apolito M, Napoli C, Montesano M, Farenza V, Uppolo V, Tafuni M, Falcone F, D'Aquino G, Calandruccio ND, Luciano F, Pensabene L, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: caracciolo d. Mol Ther Nucleic Acids. 2022 Feb 11;27:1191-1224. doi: 10.1016/j.omtn.2022.02.005. eCollection 2022 Mar 8. Mol Ther Nucleic Acids. 2022. PMID: 35282417 Free PMC article. Review.
123 results